Search
Studies * EuroSIDA * Publications * 2006-2011


EuroSIDA publications 2006-2011

Publications 2006-2011

2011

1 Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. W Bannister, A Cozzi-Lepri, J Kjær, B Clotet, A Lazzarin, JP Viard, G Kronborg, D Duiculescu, M Beniowski, L Machala, A Phillips; the EuroSIDA study group.
Journal of Antimicrobial Chemotherapy. J Antimicrob Chemother.2011 Apr;66(4):901-11. Epub 2011 Jan 31. abstract

2 Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study('). K Petoumenos, S Worm, P Reiss, S de Wit, A d'Arminio Monforte, C Sabin, N Friis-Møller, R Weber, P Mercie, C Pradier, W El-Sadr, O Kirk, JD Lundgren, M Law; for the D:A:D study group.
HIV Med. 2011 Aug;12(7):412-21. doi: 10.1111/j.1468-1293.2010.00901.x. Epub 2011 Jan 20. abstract

3 A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: Results from the EuroSIDA study. JD Kowalska, A Mocroft, B Ledergerber, E Florence, M Ristola, J Begovac, H Sambatakou, C Pedersen, JD Lundgren, and O Kirk; for the EuroSIDA study group.
HIV Clin Trials. 2011 Mar-Apr;12(2):109-17. abstract

4 Tuberculosis among HIV-postive patients across Europe: changes over time and risk factors. A Kruk, W Bannister, D Podlekareva, N Chentsova, A Rakhmanova, A Horban, P Domingo, A Mocroft, J Lundgren, O Kirk; on behalf of the EuroSIDA study group.
AIDS. 2011 Jul 31;25(12):1505-13. Epub ahead of print 2011 May 21. abstract

5 Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. JP Viard, JC Souberbielle, O Kirk, J Reekie, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, JD Lundgren, A Mocroft for the EuroSIDA Study Group.
AIDS. 2011 Jun 19;25(10):1305-1315. abstract

6 HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes. J Bohlius, K Schmidlin, F Boué, G Fätkenheuer, M May, AM Caro-Murillo, A Mocroft, F Bonnet, G Clifford, V Paparizos, JM Miro, N Obel, M Prins, G Chêne, M Egger.
Blood. 2011 Jun 9;117(23):6100-8. Epub 2011 Mar 2. abstract

7 The Coding Causes of Death in HIV (CoDe) Project- Initial Results and Evaluation of Methodology. JD Kowalska, N Friis-Møller, O Kirk, W Bannister, A Mocroft, C Sabin, P Reiss, J Gill, C Lewden, A Phillips, A d'Arminio Monforte, M Law, J Sterne, S De Wit, JD Lundgren, the CoDe working group and the D:A:D study group.
Epidemiology. 2011 Jul;22(4):516-523. abstract

8 Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA. ZV Fox, A Cozzi-Lepri, A d'Arminio Monforte, A Karlsson, AN Phillips, G Kronborg, J Kjaer, B Clotet, JD Lundgren for EuroSIDA.
Antiviral Therapy. 2011;16(5):781-5. abstract

9 Hepatitis delta in HIV-infected individuals in Europe. V Soriano, D Grint, A Monforte, A Horban, C Leen, E Poveda, F Antunes, S de Wit, J Lundgren, J Rockstroh, L Peters.
AIDS. 2011 Oct 23;25(16):1987-92. Epub ahead of print 2011 Aug 19. abstract

10 Fatal and non-fatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata. J Reekie, J Gatell, I Yust, E Bakowska, A Rakhmanova, M Losso, M Krasnov, P Francioli, J Kowalska, A Mocroft, for the EuroSIDA study group.
AIDS. 2011 Nov 28;25(18):2259-68. Epub ahead of print 2011 Sep 13. abstract

11 A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practise across Europe : A EuroSIDA study.J Reekie, P Reiss, B Ledergerber, D Sedlacek, M Parczewski, J Gatell, C Katlama, G Fatkenhaeur, JD Lundgren, A Mocroft.
HIV Med. 2011 May;12(5):259-68. doi: 10.1111/j.1468-1293.2010.00877.x. Epub 2010 Aug 31.abstract

12 A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. R Paredes, MC Puertas, W Bannister, M Kisic, A Cozzi-Lepri, C Pou, R Bellido, G Betancor, J Bogner, P Gargalianos, D Bánhegyi, B Clotet, J Lundgren, L Menéndez-Arias, J Martinez-Picado; The EuroSIDA Study Group.
J Infect Dis. 2011 Sep 1;204(5):741-52. abstract

13 Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score. A Cozzi-Lepri, MCF Prosperi, J Kjær, D Dunn, R Paredes, CA Sabin, JD Lundgren, AN Phillips, D Pillay, for the EuroSIDA and the United Kingdom CHIC/United Kingdom HDRD Studies.
PLoS One. 2011;6(11):e25665. Epub 2011 Nov 16. abstract

14 The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI(*). A Cozzi-Lepri, R Paredes, AN Phillips, B Clotet, J Kjaer, V Von Wyl, G Kronborg, A Castagna, Jr Bogner, JD Lundgren for EuroSIDA in EuroCoord.
HIV Med. 2012 Jan;13(1):62-72. doi: 10.1111/j.1468-1293.2011.00943.x. Epub 2011 Aug 17. abstract

15 Elevated triglycerides and risk of MI in HIV-positive persons, the D:A:D study. SW Worm, DA Kamara, P Reiss, O Kirk, W El-Sadr, C Fux, E Fontas, A Phillips, AD Monforte, S De Wit, K Petoumenos, N Friis-Møller, P Mercie, J Lundgren, C Sabin.
AIDS. 2011 Jul 31;25(12):1497-504. abstract

16 The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: The D:A:D Study. DA Kamara, SW Worm, P Reiss, M Rickenbach, A Phillips, O Kirk, AD Monforte, M Bruyand, M Law, S De Wit, C Smith, C Pradier, JD Lundgren, C Sabin.
J Infect Dis. 2011 Aug;204(4):521-525. abstract

17 Calendar time trends in the incidence and prevalence of triple-class viroligic failure in antiretroviral drug experienced people with HIV in Europe. F Nakagawa for the PLATO II group for COHERE in EuroCoord.
J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9. abstract

18 Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy - a European multi-cohort study. The EuroCoord-CHAIN joint project. L Wittkop, HF Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kucherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F Garcia, A Judd, K Porter, R Thiébaut, H Castro (née Green), AI van Sighem, C Colin, J Kjær, JD Lundgren, R Paredes, A Pozniak, B Clotet, A Phillips, D Pillay, G Chêne.
Lancet Infectious Diseases. 2011 May;11(5):363-371. abstract






Total EuroSIDA publications as of December 2011: 162



1 History of viral suppression on cART as a predictor of virological failure after a treatment change. J Reekie, A Mocroft, B Ledergerber, M Beniowski, B Clotet, J van Lunzen, A Chiesi, C Pradier, L Machala, J D Lundgren on behalf of the EuroSIDA Study Group.

HIV Med. 2010 Aug;11(7):469-78. abstract

2 Predictors of hepatitis B virus (HBV) genotype and viremia in HIV-infected patients with chronic hepatitis B in Europe. V Soriano, A Moocroft, L Peters, J Rockstroh, F Antunes, N Kirkby, S de Wit, A d'Arminio Monforte, R Flisiak, and J Lundgren on behalf of EuroSIDA.
Journal of Antimicrobial Chemotherapy. 2010 Mar;65(3):548-55. Epub 2010 Jan 5. article

3 Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).
Arch Intern Med. 2010 Mar 8;170(5):410-9.

4 Relationship between current level of immunodeficiency and non-AIDS defining malignancies. J Reekie, C Kosa, F Engsig, A d'Arminio Monforte, A Wiercinska-Drapalo, P Domingo, F Antunes, N Clumeck, O Kirk, JD Lundgren, A Mocroft for the EuroSIDA study group.
Cancer. 2010 Jul 26. abstract

5 Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. A Mocroft, O Kirk, P Reiss, S De Wit, D Sedlacek, M Beniowski, J Gatell, AN Phillips, B Ledergerber, JD Lundgren, for the EuroSIDA Study Group.
AIDS 2010 Jul 17;24(11):1667-78. abstract

6 Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. The Antiretroviral Therapy Cohort Collaboration Study Group (ART-CC).
Clin Infect Dis. 2010 May 15;50(10):1387-96. abstract

7 Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HV infection and a CD4 cell count <200 cells/mL? The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE).
Clinical Infectious Diseases. 2010;51(5):611-9. article

8 Estimated average annual rate of change of CD4 counts in patients on combination antiretroviral therapy. A Mocroft, AN Phillips, B Ledergerber, C Smith, JR Bogner, K Lacombe, A Wiercinska-Drapalo, P Reiss, O Kirk, JD Lundgren for the EuroSIDA study group.
Antiviral Therapy 2010. 15:563-570. article

9 Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey. JC Trullas, A Mocroft, F Cofan, J Tourret, A Moreno, CI Bagnis, CA Fux, C Katlama, P Reiss, J Lundgren, JM Gatell, O Kirk, JM Miró; the EuroSIDA Investigators.
J Acquir Immune Defic Syndr. 2010 Aug 31. [Epub ahead of print]

10 A comparison of the long term durability of nevirapine, efavirenz and lopinavir in routine clinical practise across Europe: a EuroSIDA study. J Reekie, P Reiss, B Ledergerber, D Sedlacek, M Parczewski, J Gatell, C Katlama, G Fätkenheuer, JD Lundgren, A Mocroft; for the EuroSIDA study group.
HIV Med. 2010 Aug 31. [Epub ahead of print] abstract

11 Predicting the risk of cardiovascular disease in HIV-infected patients: the Data Collecton on Adverse Effects of Anti-HIV Drugs Study. N Friis-Møller, R Thiébaut, P Reiss, R Weber, AD Monforte, S De Wit, W El-Sadr, E Fontas, S Worm, O Kirk, A Phillips, C Sabin, JD Lundgren, M Law; for the DAD study group.
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. article

12 High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. SW Worm, N Friis-Møller, M Bruyand, A D'Arminio Monforte, M Rickenbach, P Reiss, W El-Sadr, A Phillips, J Lundgren, C Sabin, for the DAD study group.
AIDS. 2010 Jan 28;24(3):427-35. PMID: 19910787 article

13 Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Worm SW, Sabin S, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Fontas E, Weller I, Phillips a, Lundgren J.
J Infect Dis. 2010 Feb 1;201(3):318-30. PubMed PMID: 20039804 article

14 Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study group. C Smith, SW Worm, N Friis-Møller, CA Sabin, A Sjøl, JD Lundrgen, R Salbøl-Brandt, M Rickenbach, P Pezzotti, E Krum, L Gras, E Balestre, A Sundström, M Delforge, E Fontas, F Torres, K Petoumenos, J Kjær, S Collins, S Storpher, G Pearce, R Rode, I Weller.
AIDS. 2010 Jun 19;24(10):1537-48.

15 HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. R Weber, C Sabin, P Reiss, S de Wit, SW Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, W El-Sadr, O Kirk, M Rickenbach, A Phillips, B Ledergerber, J Lundgren.
Antivir Ther. 2010;15(8):1077-86.

Total EuroSIDA publications as of December 2010: 144


2009

1 Hepatitis C Virus (HCV) Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1 Infected Patients with Maximum Virologic Suppression. L Peters, A Mocroft, V Soriano, J Rockstroh, P Aldins, M Losso, L Valerio, P Reiss, B Ledergerber, J Lundgren, for the EuroSIDA Study Group.

JAIDS 2009, Apr 15;50(5):457-63.


2 Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource-Limited Settings.Cozzi-Lepri A, Phillips AN, Martinez-Picado J, d'Arminio Monforte A, Katlama C, Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group.
J Infect Dis. 2009 Sep 1;200(5):687-697. PubMed PMID:19604043.

3 Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A,Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration.
AIDS. 2009 Aug 24;23(13):1689-99. PubMed PMID: 19487907.

4 Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N.
Circulation. 2009 Feb 17;119(6):805-11. Epub 2009 Feb 2. PubMed PMID: 19188509; PubMed Central PMCID: PMC2715841.

5 Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte A, Pradier C, Thiebaut R, Law M, Rickenbach M, De Wit S, Lundgren JD, Friis-Møller N.
Diabetes Care. 2009 Mar;32(3):474-80. Epub 2008 Dec 3. PubMed PMID: 19056612; PubMed Central PMCID: PMC2646032.

6 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR.
Lancet. 2009 Apr 18;373(9672):1352-63. Epub 2009 Apr 8. Review. PubMed PMID:19361855; PubMed Central PMCID: PMC2670965.

7 Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group.
AIDS. 2009 Sep 24;23(15):2029-37.

8 Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group.
Antivir Ther. 2009;14(8):1065-74.

9 Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. DN Podlekareva, A Mocroft, FA Post, V Riekstina, JM Miro, H Furrer, M Bruyand, AM Panteleev, AG Rakhmanova, E Girardi, MH Losso, JJ Roibaro, J Caylá, RF Miller, N Obel, A Skrahina, N Chentsova, JD Lundgren, O Kirk; HIV/TB Study Writing Group.
AIDS. 2009 Nov 27;23(18):2405-95. abstract

10 Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in EuroSIDA. M van Luin, WP Bannister, A Mocroft, P Reiss, G Di Perri, G Peytavin, J Molto, A Karlson, A Castagna, M Beniowski, JD Lundgren, DM Burger; the EuroSIDA study group
Antiviral Ther. 2009; 14(1):75-83. abstract

11 Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. Antiretroviral therapy cohort collaboration (ART-CC), E Lanoy, M May, A Mocroft, A Phillip, A Justice, G Chene, H Furrer, T Sterling, A d'Arminio Monforte, L Force, J Gill, R Harris, RS Hogg, J Rockstroh, M Saag, P Khaykin, F de Wolf, JA Sterne, D Costagliola.
AIDS. 2009 Oct 23;23(16):2199-2208. abstract

12 Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. DM Moore, R Harris, V Lima, B Hogg, M May, B Yip, A Justice, A Mocroft, P Reiss, F Lampe, G Chene, D Costagliola, L Elzi, MJ Mugavero, A d'Arminio Monforte, C Sabin, D Podzamczer, G Fätkenheuer, S Staszewski, J Gill, JA Sterne; Antiretroviral Therapy Cohort Collaboration.
J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):357-63. abstract

13 Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Antiretroviral Therapy Cohort Collaboration (ART-CC), A Mocroft, JA Sterne, M Egger, M May, S Grabar, H Furrer, C Sabin, G Fätkenheuer, A Justice, P Reiss, A d'Arminio Monforte, J Gill, R Hogg, F Bonnet, M Kitahata, S Staszewski, J Casabona, R Harris, M Saag.
Clin Infect Dis. 2009 Apr 15;48(8):1138-51. abstract

2008

1 The role of antiretroviral therapy on the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. CJ Smith, CH Olsen, A Mocroft, JP Viard, S Staszewski, G Panos, T Staub, A Balxhult, N Vetter, JD Lundgren for the EuroSIDA study group.
AIDS. 2008 Jan 2;22(1):47-56.abstract

2 Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. WP Bannister, L Ruiz, A Cozzi-Lepri, A Mocroft, O Kirk, S Staszewski, C Loveday, A Karlsson, A Monforte, B Clotet, JD Lundgren; EuroSIDA Study Group
AIDS. 2008 Jan 30;22(3):367 abstract

3 Regional differences in the risk of triple class failure in European patients starting cART after 1 January 1999.  A Mocroft, A Horban, B Clotet, A d’Arminio Monforte, JR Bogner, P Aldins, T Staub, F Antunes, C Katlama, JD Lundgren for the EuroSIDA study group.
HIV Med. 2008 Jan;9(1):41-6. abstract

4 Loss to follow-up in an international, multicentre observational study. A Mocroft, O Kirk, P Aldins, A Chiesi, A Blaxhult, N Chentsova, N Vetter, F Dabis, J Gatell and JD Lundgren, for the EuroSIDA study group. 
HIV Med. 2008 9(1):261-269

5 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W E l Sadr, F Dabis, S De Wit, M Law, A D´Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, I Weller, AN Phillips, JD Lundgren.
Lancet. 2008 Apr 26;371(9622):1417-26. E pub 2008 Apr 2 abstract

6 Transmitted drug resistance and association with virological and CD4 cell count response to combination antiretroviral therapy in EuroSIDA. WP Bannister, A Cozzi-Lepri, B Clotet, A Mocroft, J Kjær, P Reiss, V von Wyl, A Lazzarin, C Katlama, AN Phillips, L Ruiz, JD Lundgren and the EuroSIDA study group.
J Acquir Immune Defic Syndr. 2008 Jun 9. [Epub ahead of print] abstract

7 Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. CJ Smith, A Mocroft, JD Lundgren; EuroSIDA Study Group.
AIDS. 2008 May 11;22(8):997-8.

8 Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. K Deforche, A Cozzi-Lepri, K Theys, B Clotet, RJ Camacho, J Kjær, K Van Laethem, AN Phillips, Y Moreau, JD Lundgren, and A-M Vandamme on behalf of the EuroSIDA Study Group.
Antivir Ther. 13:399-407

9 Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. D Podlekareva, A Mocroft, O Kirk, P Reiss, P Aldins, C Katlama, H Kovari, HJ Stellbrink, A D'Arminio Monforte, JD Lundgren.
Scand J Infect Dis. 2008 Jun 18:1-6. [Epub ahead of print] abstract

10 The clinical application of the EuroSIDA risk score. J Reekie, A Mocroft, O Kirk and J D Lundgren.
AIDS & Hepatitis digest. 2008; 126:1-5 

11 Incidence of abacavir hypersensitivity reactions in EuroSIDA. WP Bannister, N Friis-Møller, A Mocroft, J-P Viard, J van Lunzen, O Kirk, P Gargalianos, D Bánhegyi, A Chiesi, JD Lundgren, and the EuroSIDA study group.
Antivir Ther. 2008;13(5):687-96 abstract

12 The EuroSIDA study: regional differences in HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe - a review of published results. D Podlekareva, W Bannister, A Mocroft, L Abrosimova, I Karpov, JD Lundgren, O Kirk for the EuroSIDA study group
Cent Eur J Public Health. 2008 Sep;16(3):99-105.abstract Review. PubMed PMID: 18935770.

13 Detection of HIV drug resistance during antiretrovrial treatment and clinical progression in a large European cohort study. A Cozzi-Lepri, AN Phillips, B Clotet, A Mocroft, L Ruiz, O Kirk, A Lazzarin, A Wiercinska-Drapalo, A Karlsson, JD Lundgren for the EuroSIDA Study Group.
AIDS. 2008 Oct 18;22(16):2187-98. abstract PubMed PMID: 18832882.

14 Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? J Reekie, A Mocroft, H Sambatakou, L Machala, A Chiesi, J van Lunzen, N Clumeck, O Kirk, B Gazzard, JD Lundgren for the EuroSIDA study group.
AIDS. 2008 Nov 12;22(17):2381-90. abstract

15 Spontaneous viral clearance, viral load and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. V Soriano, A Mocroft, J Rockstroh, B Ledergerber, B Knysz, S Chaplinskas, L Peters, A Karlsson, C Katlama, C Toro, B Kupfer, M Vogel and J Lundgren, for the EuroSIDA Study Group. 
J Infect Dis. 2008 Nov 1;198(9):1337-44. abstract

16 The ART Cohort Collaboration: Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? Writing committee: Michael J. Mugavero, Margaret May, Ross Harris, Michael S. Saag, Dominique Costagliola, Matthias Egger, Andrew Phillips, Huldrych Günthard, Francois Dabis, Robert Hogg, Frank de Wolf, Gerd Fatkenheuer, John Gill, Amy Justice, Antonella D'Arminio Monforte, Fiona Lampe, Jose Maria Miró, Schlomo Staszewski , Mari Kitahata and Jonathan A C Sterne.
AIDS 2008; 22: 2481-2492.

17 The ART Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Writing committee: Hogg, R., Lima V., Sterne, J.A.C. Grabar, S., Battegay, M., Bonarek, M., D’Arminio Monforte, A., Esteve, A., Gill, M.J., Harris, R., Justice, A., Hayden, A., Lampe, F., Mocroft, A., Mugavero, M.J., Staszewski, S., Wasmuth J.C., van Sighem, A., Kitahata, .M, Guest, J., Egger, M. and May, M.
Lancet 2008; 372: 293-299. PubMed PMID: 18657708

18 HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.
AIDS. 2008 Oct 18;22(16):2143-53. PubMed PMID: 18832878; PubMed Central PMCID: PMC2715844.

19 Response to combination antiretroviral therapy: variation by age. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group.
AIDS. 2008 Jul 31;22(12):1463-73. PubMed PMID: 18614870.

20 Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA,d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD.
Clin Infect Dis. 2008 Apr 1;46(7):1101-10. PubMed PMID: 18461712; PubMed Central PMCID:PMC2702541.

21 Antiretroviral Therapy Cohort Collaboration: Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M, Egger M.
Antivir Ther. 2008;13(8):959-67. PubMed PMID: 19195321.

22 Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. S de WIt, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, W El-Sadr, A d´Arminio Monforte, E Fontas, MG Law, N Friis-Møller, JD Lundgren.
Diabetes Care. 2008 Feb 11 abstract

23 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. The SMART/INSIGHT and the D:A:D study groups. Writing committee: JD Lundgren, J Neuhaus, A Babiker, D Cooper, D Duprez, W El-Sadr, S Emery, F Gordin, J Kowalska, A Phillips, RJ Prineas, P Reiss, C Sabin, R Tracy, R Weber, B Grund and JD Neaton.
AIDS.2008, 22:F17-F24 abstract

2007

1 Evolution of drug resistance in HIV infected patients remaining on a virologically failing cART regimen. A Cozzi-Lepri, AN Phillips, L Ruiz, B Clotet, C Loveday, J Kjær, H Mens, N Clumeck, L Viksna, F Antunes, L Machala, JD Lundgren.
AIDS. 2007 Mar 30;21(6):731-32 abstract

2 Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.C Holkmann Olsen, A Mocroft, O Kirk, S Vella, A Blaxhult, N Clumeck, M Fisher, C Katlama, AN Phillips and JD Lundgren for the EuroSIDA study group.
HIV Med. 2007 Mar;8(2):96-104 abstract

3 Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. Writing committee: N Friis-Møller, P Reiss, CA Sabin, R Weber, A D´Arminio Monforte, W El-Sadr, R Thiebaut, S de Wit, O Kirk, E Fontas, MG Law, A Phillips, JD Lundgren on behalf of the D:A:D study group.
N Engl J Med. 2007 April 26;356:1723-35 abstract

4 Chronic renal failure among HIV-1-infected patients. A Mocroft, O Kirk, J Gatell, P Reiss, P Gargalianos, K Zilmer, M Beniowski, J-P Viard, S Staszewski, and JD Lundgren for the EuroSIDA study group.
AIDS. 2007 May 31, 21(9):1119-1127 abstract

5 Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. A Mocroft, AN Phillips, J Gatell, B Ledergerber, M Fisher, N Clumeck, M Losso, A Lazzarin, JD Lundgren for the EuroSIDA study group.
Lancet. 2007 July 19, online link

6 Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy : The EuroSIDA risk-score. A Mocroft, B Ledergerber, K Zilmer, O Kirk, JP Viard, P Reiss, A Lazzarin, L Machala, AN Phillips, JD Lundgren for the EuroSIDA study group.
AIDS. 2007 Sep;21(14):1867-1875.  abstract

7 Current haemoglobin levels are more predictive of disease progression than haemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV-1 infection. JD Kowalska, A Mocroft, A Blaxhult, R Colebunders, J van Lunzen, D Podlekareva, A-BE Hansen, L Machala, I Yust and T Benfield for the EuroSIDA Study Group.
AIDS Res Hum Ret. 2007; 23 (10): 1183-1188

8 Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue based regimens in ART-naïve and experienced patients. F Ceccherini-Silberstein, A Cozzi-Lepri, L Ruiz, A Mocroft, AN Phillips, C Holkmann-Olsen, JM Gatell, FH Günthard, P Reiss, CF Perno, B Clotet, and JD Lundgren for the EuroSIDA study group.
J Infect Dis. 2007 Oct 15;196(8):1180-90. Epub 2007 Sep 19. abstract

9 The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. ZV Fox, AM Geretti, J Kjaer, UB Dragsted, AN Phillips, J Gerstoft, S Staszewski, B Clotet, V von Wyl, JD Lundgren.
AIDS. 2007 Oct 1;21(15):2033-42. abstract

10 Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced HIV-infected patients with high and low CD4 counts. A Mocroft, S Staszewski, R Weber, J Gatell, J Rockstroh, J Gasiorowski, G Panos, A d’Arminio Monforte, A Rakhmanova, AN Phillips, JD Lundgren
Antivir Ther. 2007;12(3):325-33. Erratum in: Antivir Ther. 2007;12(4):577. abstract

11 The Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA) and The ART Cohort Collaboration: Tuberculosis after Initiation of Antiretroviral Therapy in Low-Income and High-Income Countries. CID 2007;45:1518–1521

12 The ART Cohort Collaboration: Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1 Infected Patients. Writing committee: Jonathan A C Sterne, Margaret May, Caroline Sabin, Andrew Phillips, Dominique Costagliola, Geneviève Chêne, Amy C Justice, Frank de Wolf, Robert Hogg, Manuel Battegay, Antonella D’Arminio Monforte, Norbert Schmeisser, Schlomo Staszewski, John Gill and Matthias Egger.
J Acquir Immune Defic Syndr 2007; 46:607–615.13

13 A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men.May M, Sterne JA, Shipley M, Brunner E, d'Agostino R, Whincup P, Ben-Shlomo Y, Carr A, Ledergerber B, Lundgren JD, Phillips AN, Massaro J, Egger M.
Int J Epidemiol, 2007 Dec;36(6):1309-18.

14 HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. Sterne JA, May M, Bucher HC, Ledergerber B, Furrer H, Cavassini M, Bernasconi E, Hirschel B, Egger M;
Swiss HIV Cohort. J Intern Med 2007 261:255-67.

2006

1 Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and the ART Cohort Collaboration. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg D, Balestre E, Sterne J, May M, Egger M.
Lancet 2006 367: 817-824

2 The Use of the Framingham Equation to Predict Myocardial Infarctions in HIV-infected Patients: Comparison with Observed Events in the D:A:D Study.

MG Law, N Friis-Møller, WM El-Sadr, R Weber, P Reiss, A D'Arminio Monforte, R Thiébaut, L Morfeldt, S De Wit, C Pradier, G Calvo, O Kirk, CA Sabin, AN Phillips, and JD Lundgren for the D:A:D Study Group.
HIV Med. 2006;7;218-230. abstract

3 Relationship between antiretrovirals used as part of a cART regimen and CD4 count increases in patients with suppressed viremia. A Mocroft,  A Phillips, B Ledergerber, C Katlama, A Chiesi F Goebel, B Knysz, F Antunes, P Reiss, J Lundgren for the EuroSIDA study group.
AIDS. 2006 May 12;20(8):1141-1150 abstract

4 The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. A Mocroft, J Neaton, J Bebchuk, S Staszewski, F Antunes, B Knysz, M Law, AN Phillips, J Lundgren for the EuroSIDA and ESPRIT study groups.
Clin Trials. 2006 May 206;3(2):119-132 abstract

5  Regional changes over time in initial virological response rates to combination antiretroviral therapy across Europe. W Bannister, O Kirk, J Gatell, B Knysz, J-P Viard, H Mens, A D'Arminio Monforte, A Phillips, A Mocroft, J Lundgren for the EuroSIDA study group. 
J Acquir Immune Defic Syndr. 2006 Jun;42(2):229-237 abstract

6 Factors associated with development of opportunistic infections in HIV-1 infected adults with high CD4 cell counts: a EuroSIDA study. D Podlekareva, A Mocroft, UB Dragsted, B Ledergerber, M Beniowski, A Lazzarin, J Weber, N Clumeck, N Vetter, A Phillips, and JD Lundgren for the EuroSIDA study group
J Infect Dis. 2006 Sep 1; 194(5):663-41 abstract

7 Liver-related deaths among persons infected with the human immunodeficiency virus: The D:A:D Study. Writing committee: R Weber, CA Sabin, N Friis-Møller, P Reiss, WM. El-Sadr, O Kirk, F Dabis, MG Law, C Pradier, S De Wit, B Åkerlund, G Calvo, A d’Arminio Monforte, M Rickenbach, B Ledergerber, AN Phillips, and JD Lundgren
Arch Intern Med. 2006;166:1632-1641 abstract

8 Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. M Puoti, A Cozzi-Lepri, C Arici C, NF Moller, JD Lundgren, B Ledergerber, M Rickenbach, I Suarez-Lozano, M Garrido, F Dabis, M Winnock, L Milazzo, A Gervais, F Raffi, J Gill, J Rockstroh, N Ourishi, C Mussini, A Castagna, A De Luca, A Monforte; HBV-HIV International Intercohort Study Group. 
Antivir Ther. 2006;11(5):567-74 abstract

9 HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. M May, J Sterne, D Costagliola, M Egger, C Sabin, A Phillips, A Justice, F Dabis, J Gill, J Lundgren, R Hogg, F de Wolf, G Fätkenheuer, S Staszewski, and A d´Arminio Monforte for  The Antiretroviral Therapy (ART) Cohort Collaboration.
Lancet. 2006 Aug 5;368(9534):451-8 abstract

10 HIV-1 subtypes and response to combination antiretroviral therapy in Europe. WP Bannister, L Ruiz, C Loveday, S Vella, K Zilmer, J Kjær, B Knysz, AN Phillips, A Mocroft, JD Lundgren for the EuroSIDA study group
Antiviral Ther 2006; 11: 707-715 abstact

11 Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. A Mocroft, J Rockstroh, V Soriano, O Kirk, J-P Viard, S Caplinskas, J Gasiorowski, A Chiesi, AN Phillips, JD Lundgren for the EuroSIDA Study.
Scand J Inf Dis. 2006;38:1092-1097

12 Comparison of single and boosted-protease-inhibitor versus non-nucleoside reverse transcriptase inhibitor containing cART regimens in antiretroviral naïve patients starting cART after 1/1/2000. A Mocroft, A Horban, N Clumeck, HJ Stellbrink, A d’Arminio Monforte, K Zilmer, O Kirk, J Gatell, AN Phillips, JD Lundgren for the EuroSIDA study group
HIV Clin Trials. 2006 Nov-Dec;7(6):271-84 abstract

13 The ART Cohort Collaboration. Rates of disease progression according to initial HAART regimen: A collaborative analysis of 12 prospective cohort studies. Writing committee: Robert Hogg, Margaret May, Andrew Phillips, Dominique Costagliola, Jonathan Sterne, Caroline Sabin, Frank De Wolf, Bruno Ledergerber, Antonella D'Arminio Monforte, Amy Justice, John Gill, Gregory Fusco, Schlomo Staszewski, Jurgen Rockstroh, Geneviève Chêne and Matthias Egger.
Journal of Infectious Diseases 2006 194: 612-622